Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1936 to 1950 of 8917 results

  1. Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

    Awaiting development Reference number: GID-TA11753 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Iptacopan for treating primary IgA nephropathy [ID6640]

    Awaiting development Reference number: GID-TA11844 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development Reference number: GID-TA11363 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    Awaiting development Reference number: GID-TA11670 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    Awaiting development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  10. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  12. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    Awaiting development Reference number: GID-TA11886 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

    Health technology evaluations
    In development

  14. Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]

    Awaiting development Reference number: GID-TA11904 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]

    Awaiting development Reference number: GID-TA11905 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development